Connect Biopharma Holdings Limited (CNTB): Price and Financial Metrics

Connect Biopharma Holdings Limited (CNTB): $1.05

0.10 (-8.70%)

POWR Rating

Component Grades








Add CNTB to Watchlist
Sign Up

Industry: Biotech




#251 of 398

in industry

CNTB Price/Volume Stats

Current price $1.05 52-week high $2.84
Prev. close $1.15 52-week low $0.53
Day low $1.03 Volume 145,700
Day high $1.16 Avg. volume 245,815
50-day MA $1.24 Dividend yield N/A
200-day MA $1.09 Market Cap 57.83M

CNTB Stock Price Chart Interactive Chart >

Connect Biopharma Holdings Limited (CNTB) Company Bio

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

CNTB Latest News Stream

Event/Time News Detail
Loading, please wait...

CNTB Latest Social Stream

Loading social stream, please wait...

View Full CNTB Social Stream

Latest CNTB News From Around the Web

Below are the latest news stories about CONNECT BIOPHARMA HOLDINGS LTD that investors may wish to consider to help them evaluate CNTB as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a hot topic on Wednesday as we check out all of the biggest movements happening this morning!

William White on InvestorPlace | November 22, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!

William White on InvestorPlace | November 21, 2023

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Simcere has been granted an exclusive right to develop, manufacture, and commercialize rademikibart for all indications in Greater ChinaConnect Biopharma retains rights to develop and commercialize rademikibart in all other markets and completed the pivotal atopic dermatitis (AD) trial in ChinaRademikibart is a human monoclonal antibody against IL-4Rα, a common subunit for IL-4R and IL-13 receptors being developed for the treatment of Th2 driven inflammatory diseases SAN DIEGO, CA and TAICANG, C

Yahoo | November 21, 2023

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Clinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks (Q2W) and every four weeks (Q4W) dosing regimens Approximately 90% of patients on Q4W dose maintained both IGA 0/1 and EASI-75 through Week 52 Over 36 weeks of treatment in Stage 2 of the study, the percentage of patients achieving IGA 0/1 and EASI-75 continued to increaseRademikibart continued to be well tolerated over 52 weeks of treatmentA conference

Yahoo | November 21, 2023

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will announce topline results from the Stage 2 (maintenance period) of its China pivotal trial evaluating rademiki

Yahoo | November 20, 2023

Read More 'CNTB' Stories Here

CNTB Price Returns

1-mo -30.46%
3-mo N/A
6-mo -7.08%
1-year 46.55%
3-year N/A
5-year N/A
YTD 21.00%
2022 -83.15%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!